HGEN [NASD]
Humanigen, Inc.
Index- P/E- EPS (ttm)-3.18 Insider Own21.12% Shs Outstand65.59M Perf Week12.78%
Market Cap149.94M Forward P/E5.27 EPS next Y0.39 Insider Trans7.32% Shs Float56.39M Perf Month-11.35%
Income-192.40M PEG- EPS next Q-0.31 Inst Own42.00% Short Float11.23% Perf Quarter-0.98%
Sales4.10M P/S36.57 EPS this Y-66.90% Inst Trans0.05% Short Ratio4.07 Perf Half Y-70.28%
Book/sh-0.38 P/B- EPS next Y81.80% ROA-224.90% Target Price16.43 Perf Year-89.01%
Cash/sh0.93 P/C2.18 EPS next 5Y12.50% ROE- 52W Range1.67 - 23.53 Perf YTD-45.43%
Dividend- P/FCF- EPS past 5Y21.90% ROI- 52W High-91.37% Beta-0.95
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low21.56% ATR0.21
Employees11 Current Ratio1.00 Sales Q/Q100.00% Oper. Margin- RSI (14)47.21 Volatility9.71% 10.91%
OptionableYes Debt/Eq- EPS Q/Q73.90% Profit Margin- Rel Volume0.73 Prev Close2.03
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.56M Price2.03
Recom2.30 SMA203.94% SMA50-21.54% SMA200-64.13% Volume0 Change0.00%
Sep-10-21Downgrade Jefferies Buy → Hold $9
Sep-09-21Reiterated H.C. Wainwright Buy $36 → $28
Sep-09-21Downgrade JP Morgan Neutral → Underweight
Sep-09-21Downgrade Credit Suisse Outperform → Neutral
Jun-11-21Initiated Credit Suisse Outperform $28
May-07-21Initiated Oppenheimer Outperform $30
Feb-23-21Initiated JP Morgan Neutral $21
Dec-23-20Initiated National Securities Buy $35
Dec-22-20Initiated Jefferies Buy $27
Oct-21-20Initiated Cantor Fitzgerald Overweight $25
Oct-14-20Initiated H.C. Wainwright Buy $31
Oct-01-20Initiated ROTH Capital Buy $25
May-11-22 08:43PM  
May-09-22 06:15AM  
May-05-22 04:00PM  
May-04-22 07:00AM  
Apr-19-22 06:30AM  
Apr-07-22 01:35PM  
Mar-17-22 03:47PM  
Feb-28-22 01:05PM  
Feb-25-22 05:55AM  
Feb-11-22 05:55AM  
Feb-09-22 11:55PM  
Feb-08-22 11:55PM  
Feb-06-22 08:26AM  
Jan-18-22 05:55AM  
Jan-10-22 05:55AM  
Jan-06-22 03:11PM  
Jan-05-22 06:05AM  
Jan-04-22 05:55AM  
Jan-03-22 05:55AM  
Dec-15-21 08:59AM  
Dec-01-21 06:45PM  
06:30PM  
Nov-22-21 06:30AM  
Nov-16-21 07:47AM  
Nov-12-21 04:00PM  
Nov-11-21 06:30AM  
Nov-07-21 08:34AM  
Nov-05-21 10:34AM  
07:04AM  
Nov-02-21 08:30AM  
Oct-26-21 05:31PM  
06:30AM  
Oct-22-21 07:00AM  
Oct-20-21 07:00AM  
Oct-19-21 07:00AM  
Oct-11-21 12:53PM  
12:23PM  
Oct-08-21 02:00AM  
Oct-04-21 11:00PM  
Oct-01-21 09:00AM  
Sep-29-21 08:00AM  
Sep-28-21 08:28AM  
Sep-27-21 10:58AM  
Sep-21-21 05:02PM  
Sep-20-21 12:38AM  
Sep-14-21 12:56PM  
Sep-10-21 01:10PM  
11:52AM  
Sep-09-21 09:43PM  
02:15PM  
12:16AM  
Aug-25-21 09:14AM  
Aug-12-21 04:00PM  
Aug-09-21 03:19AM  
Aug-04-21 06:00AM  
Aug-02-21 02:02PM  
Jul-30-21 11:06AM  
Jul-26-21 08:00AM  
Jul-22-21 09:59AM  
Jul-13-21 06:51PM  
Jul-12-21 08:40AM  
Jul-09-21 06:30AM  
Jun-28-21 11:46AM  
Jun-25-21 02:27AM  
Jun-14-21 06:30AM  
Jun-07-21 08:00AM  
Jun-03-21 08:00AM  
May-28-21 09:00AM  
May-26-21 08:30AM  
May-19-21 07:00AM  
May-17-21 08:00AM  
May-13-21 04:01PM  
10:15AM  
May-11-21 04:19AM  
May-05-21 11:53AM  
Apr-21-21 07:00AM  
Apr-19-21 07:00AM  
Apr-09-21 08:19AM  
08:02AM  
Apr-06-21 02:02PM  
Mar-30-21 08:08PM  
Mar-29-21 04:11PM  
07:00AM  
06:00AM  
Mar-19-21 07:00AM  
Mar-12-21 01:30AM  
Mar-10-21 04:01PM  
04:00PM  
Mar-08-21 08:34AM  
Mar-05-21 04:32PM  
Mar-02-21 07:00AM  
Feb-25-21 07:30AM  
Feb-11-21 07:30AM  
Feb-08-21 07:00AM  
Feb-04-21 02:37PM  
Feb-03-21 07:00AM  
Jan-29-21 07:00AM  
Jan-27-21 07:00AM  
07:00AM  
Jan-25-21 01:21PM  
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which has completed pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chappell DaleChief Scientific OfficerMar 11Buy3.001,000,0003,000,0007,944,985Mar 15 06:23 PM
Kilcoyne AdrianChief Medical OfficerMar 09Buy2.785,00013,90012,000Mar 14 04:37 PM
Kilcoyne AdrianChief Medical OfficerMar 08Buy2.537,00017,7107,000Mar 14 04:37 PM
Durrant CameronChief Executive OfficerMar 02Buy2.3440,00093,60070,000Mar 04 06:06 AM
Jordan Edward P.Chief Commercial OfficerMar 02Buy2.3212,50029,00012,500Mar 04 06:05 AM
Chappell DaleChief Scientific OfficerAug 12Sale17.1657,551987,564873,693Aug 13 09:28 PM
Chappell DaleChief Scientific OfficerAug 11Sale17.07109,6471,872,146878,009Aug 13 09:28 PM
Chappell DaleChief Scientific OfficerJul 29Sale17.0329,394500,703884,029Jul 30 09:01 PM
Chappell DaleChief Scientific OfficerJul 28Sale17.049,692165,162886,233Jul 30 09:01 PM
Chappell DaleChief Scientific OfficerJul 23Sale17.045,58495,155886,960Jul 23 08:32 PM
Chappell DaleChief Scientific OfficerJul 22Sale17.04178,0053,032,796887,379Jul 23 08:32 PM
Chappell DaleChief Scientific OfficerJul 21Sale17.14132,7642,275,124900,729Jul 23 08:32 PM
Chappell DaleChief Scientific OfficerJul 14Sale17.0615,177258,847910,686Jul 16 08:28 PM
Chappell DaleChief Scientific OfficerJul 09Sale17.37296,0365,142,767911,824Jul 09 09:01 PM
Chappell DaleChief Scientific OfficerJul 08Sale17.1748,010824,111934,027Jul 09 09:01 PM
Chappell DaleChief Scientific OfficerJun 25Sale17.801,000,00017,803,500972,361Jun 25 09:01 PM
Chappell DaleChief Scientific OfficerJun 24Sale18.37139,5292,563,8311,047,361Jun 25 09:01 PM
Chappell DaleChief Scientific OfficerJun 23Sale18.28133,1262,434,1821,057,826Jun 25 09:01 PM
Chappell DaleChief Scientific OfficerJun 18Sale18.50402,4807,445,5581,067,811Jun 21 08:57 PM
Chappell DaleChief Scientific OfficerJun 17Sale19.17181,4233,478,4411,097,997Jun 21 08:57 PM
Chappell DaleChief Scientific OfficerJun 16Sale19.41158,4863,076,1871,111,604Jun 21 08:57 PM
Durrant CameronChief Executive OfficerJun 14Sale20.6481,4411,680,93430,000Jun 16 09:40 PM
Jordan Edward P.Chief Commercial OfficerJun 08Option Exercise9.6514,700141,85514,700Jun 09 05:10 PM
Jordan Edward P.Chief Commercial OfficerJun 08Sale20.0814,700295,1760Jun 09 05:10 PM
Chappell DaleChief Scientific OfficerJun 07Sale19.0880,6361,538,7931,124,334Jun 09 04:45 PM
Chappell DaleChief Scientific OfficerJun 04Sale18.46127,0842,346,4151,137,066Jun 04 06:07 PM
Chappell DaleChief Scientific OfficerJun 03Sale18.37191,1543,511,3081,157,132Jun 04 06:07 PM
Chappell DaleChief Scientific OfficerJun 02Sale19.0176,1261,447,2691,187,314Jun 04 06:07 PM